
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow is well-positioned for future growth and success, with strong second quarter outperformance and continued momentum in new account openings, record levels of ordering physicians, and margin expansion. The recent positive reimbursement implementation for its emerging plaque business, coupled with the company's core US FFRCT business delivering excellent performance, suggests a bright future ahead for HeartFlow. The company's strong financial outlook, with projected revenues of $305.8 million in 2026, indicates a high growth potential with potential for further margin expansion and upside to estimates driven by new account adds and incremental plaque analysis reimbursement. While there are potential risks in the form of competition, reimbursement changes, and financial risk, we believe the company's premium valuation is justified and recommend investing in HeartFlow's stock for long-term growth potential.
Bears say
HeartFlow is facing competitive risks as there are other AI-based platforms using CCTA data to diagnose CAD, which may lead to loss of market share. While the company has demonstrated strong business momentum, the TAM opportunity in the Plaque category might be overestimated, and relying solely on CT scanner manufacturers as partners poses a risk. Additionally, the evolving regulations around the use of AI in medical technology could impact the company's growth potential.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares